In this episode, host Shikha Jain, MD, speaks with Cyclacel CEO, Spiro Rombotis, MPH, about developing techniques and therapies for drug development, how technology has affected these advancements and more.
• Welcome to another exciting episode of Oncology Overdrive 1:15
• About Rombotis 1:23
• The interview 2:21
• Can you tell us about how you ended up in the biotech and pharma spaces? 2:41
• How did you transition to the first CEO of Cyclacel, and what has kept you in the same space for over three decades? 4:45
• Is this how you envisioned your career? How did this vision evolve over the course of your career? 8:53
• What does Cyclacel do, and can you describe the types of innovation you are doing there? 10:19
• With all this new and exciting technology in the field, where do you see epigenetics and precision oncology going in the next ten to twenty years? 15:46
• What are your thoughts on AI in the oncology space? 22:21
• Jain and Rombotis on checks and balances when it comes to AI use in cancer care and clinical trials. 27:53
• What's next for you? 30:53
• If someone could only listen to the last few minutes of this episode, what would you want them to take away? 36:18
• How to contact Rombotis 40:25
• Thanks for listening 40:43
Spiro Rombotis, MPH, is the CEO of Cyclacel. He has over 36 years at three public biotechs and two pharmas.
We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rombotis can be reached via email srombotis@cyclacel.com.
Disclosures: Jain reports no relevant financial disclosures. Rombotis reports Cyclacel Ltd employment and stock ownership.
